-
Product Insights
Likelihood of Approval Analysis for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Overview How likely is it that the drugs in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute...
-
Product Insights
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2023’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Sector Analysis
NewArgentina Statutory and Private Employee Benefits, 2024 Update
Argentina Statutory and Private Employee Benefits Overview The Argentina social security system is comprehensive covering a wide variety of benefits such as retirement, death in service, long-term disability, short-term sickness, medical, workers’ compensation insurance, and maternity and paternity benefits. Furthermore, in Argentina, employers offer additional benefits to their employees through a defined contribution pension system, group health insurance plans, group life insurance plans, and a group personal accident insurance plan. The defined contribution pension plans are not too prevalent in...
-
Sector Analysis
NewCzech Republic Statutory and Private Employee Benefits, 2024 Update
Czech Republic Statutory and Private Employee Benefits Report Overview The Czech Republic has a well-developed social security system. Employers, employees, and self-employed people contribute to the social security schemes. The country’s social security system is built on three pillars: compulsory social insurance, state social support system, and social assistance. Compulsory social insurance covers pension insurance, health insurance, and the national employment policy system. The non-contributory state social support system supports families with dependent children. The final pillar, tax-financed social assistance,...
-
Sector Analysis
NewPeru Statutory and Private Employee Benefits, 2024 Update
Peru Statutory and Private Employee Benefits Overview The social security system in Peru is undergoing significant change. The informal nature of the labor market is the reason for low social security contributions. Most workers are self-employed and there are lack of information and valuation within the system. In the early 1990s, the social security system established the Sistema Privado de Pensiones (private pension system, or SPP) to provide benefits in the event of old age, disability, and death. This was...
-
Product Insights
Likelihood of Approval Analysis for Trypanosomiasis
Overview How likely is it that the drugs in Trypanosomiasis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trypanosomiasis Overview Trypanosomiasis, also known as sleeping sickness in humans and nagana in...
-
Sector Analysis
Norway Statutory and Private Employee Benefits, 2024 Update
Norway Statutory and Private Employee Benefits Overview The Norwegian employee benefits market is predominantly controlled by the public social security system. However, the growth of labor-intensive industries has fuelled the growth of the country’s private benefits market over the last decade. In Norway, general social insurance schemes are provided to citizens through the public social security system, which is overseen by the Norwegian Labor and Welfare Administration (Arbeids- og velferdsetaten; NAV). This system is important to the welfare system of...
-
Sector Analysis
Russia Statutory and Private Employee Benefits, 2024 Update
Russia Statutory and Private Employee Benefits Overview Russia underwent major economic and political changes following the collapse of the Soviet Union in the 1990s. During this two-decade transition period, several changes were made to the country's social security system. The development of private employee benefit plans took place. A three-tier pension system was established. Cost-of-living compensation was set up. The current geopolitical situation in Russia is causing significant stress and anxiety for the Russian as well as MNCs’ employers. Companies...